Toronto Dominion Bank Takes Position in Bruker Co. (NASDAQ:BRKR)

Toronto Dominion Bank bought a new position in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 50,000 shares of the medical research company's stock, valued at approximately $2,931,000.

A number of other large investors have also recently made changes to their positions in the company. London Co. of Virginia lifted its stake in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Brown Advisory Inc. lifted its stake in shares of Bruker by 10.1% during the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock worth $118,806,000 after acquiring an additional 185,912 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Bruker by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock worth $118,081,000 after acquiring an additional 20,273 shares during the last quarter. FIL Ltd boosted its holdings in Bruker by 262.3% during the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after acquiring an additional 1,420,102 shares during the period. Finally, Sculptor Capital LP grew its position in Bruker by 484.1% in the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after acquiring an additional 1,420,569 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Down 0.3%

NASDAQ:BRKR opened at $36.34 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker Co. has a 1-year low of $34.10 and a 1-year high of $78.59. The company has a 50-day moving average of $39.65 and a 200 day moving average of $49.92. The firm has a market cap of $5.51 billion, a PE ratio of 47.82, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. During the same quarter in the previous year, the business posted $0.53 EPS. The company's quarterly revenue was up 11.0% compared to the same quarter last year. As a group, research analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. Bruker's dividend payout ratio is currently 38.46%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Barclays decreased their target price on Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Stifel Nicolaus decreased their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Citigroup restated a "neutral" rating and issued a $40.00 target price (down from $50.00) on shares of Bruker in a research note on Thursday. Finally, UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $59.10.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.